specialising in pharmaceutical intermediates and speciality chemicals.Evolution of Business The company is changing its focus from Intermediates for Off-patent and generic drugs towards patented molecules requiring strong technical know how. The revenue contribution from Intermediates has also shifted from 90% to <60%.
The company's board has appointed Ms. Shruti Sohane as an Additional Non-Executive Independent Director for a five-year term, effective immediately, pending shareholder approval. Her appointment strengthens corporate governance with her legal and compliance expertise. The board also re-appointed M/s. M. I. Prajapati & Associates as Cost Auditor for the year...
Shree Ganesh Remedies Limited has published newspaper advertisements regarding its financial results for the quarter ended June 30, 2025. This disclosure makes the latest financial performance data publicly available. Shareholders can now access these important updates, providing transparency on the company's recent operational performance and financial standing, which is crucial...
Shree Ganesh Remedies Limited has released its Investor Presentation for the financial results of the quarter ended June 30, 2025. The company experienced moderated Q1 FY26 performance due to repricing of CRAMS contracts, European market headwinds, and intensified domestic competition, which also led to moderated EBITDA margins. Despite near-term challenges,...
Shree Ganesh Remedies Limited reported Q1FY26 financial results, showing moderated growth. Revenue was 24.67 Cr (-0.45% YoY), while PAT stood at 3.44 Cr (-26.09% YoY), and EBITDA was 7.30 Cr (-10.19% YoY) with margins at 29.6%. The company attributed this to contract repricing in its CRAMS business, European market headwinds,...
Shree Ganesh Remedies has received a GST summons for an investigation concerning alleged expired stock at a company warehouse. The potential GST liability involved is approximately Rs. 0.89 Crore. However, the company, with support from its legal and tax counsel, considers these claims untenable under law and does not expect...
